Please assess the completion status of the following clinical trial:

Trial Title: A Study of Duloxetine in Major Depressive Disorder (MDD) and Associated Painful Symptoms

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Meets criteria for Major Depressive Disorder (MDD) as defined by Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) and confirmed by Mini International Neuropsychiatric Interview (MINI)~* Montgomery-Asberg Depression Rating Scale (MADRS) total score of greater than or equal to 20 during the Screening Phase~* At least 1 previous episode of depression~* Painful physical symptoms with a score greater than or equal to 3 on the Brief Pain Inventory-Short Form (BPI-SF) average pain question during the Screening Phase~* A Clinical Global Impression of Severity (CGI-S) score of greater than or equal to 4 during the Screening Phase~* Written informed consent~Exclusion Criteria:~* Currently enrolled in, or discontinued within the last 30 days from, a clinical trial involving an off-label use of an investigational drug or device~* Previously completed or withdrawn from this study or any other study investigating duloxetine~* Women of child-bearing potential who are not using a medically accepted means of contraception~* Any current (within the past 6 months) DSM-IV-TR primary Axis I diagnosis other than MDD~* History of alcohol abuse or dependence within 1 year immediately prior to being screened for the study~* Any prior history of bipolar disorder, psychosis, or schizophrenia~* Have an Axis II disorder that would interfere with study compliance~* Lack of a response of any (lifetime of subject) episode of major depression greater than or equal to 2 adequate courses of antidepressant therapy, defined as a clinically appropriate dose for a minimum of 4 weeks or, alternatively, in the judgment of the investigator, the subject meets criteria for treatment-resistant depression~* Have previously received treatment of MDD or Generalized Anxiety Disorder (GAD) with an adequate trial of duloxetine and did not respond or could not tolerate duloxetine~* Diagnosis of acute liver injury or severe cirrhosis~* Uncontrolled narrow-angle glaucoma~* Positive urine drug screen for any substance of abuse.~* A serious medical illness, including any cardiovascular, hepatic, renal, respiratory, hematologic, endocrinologic, or neurologic disease, or a clinically significant laboratory abnormality that is not stabilized or is anticipated to require intervention~* A history of substance abuse or dependence within 1 year before being screened for the study~* History of a serious suicide attempt or subject judged clinically to be at serious suicidal risk~* Require continuous use of opioid analgesics for 6 or more months because of chronic pain~* Pain of a known origin~* Meets criteria for fibromyalgia as defined by the American College of Rheumatology~* Experiences greater than or equal to 1 migraine headache per week~* Have had electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS), or vagus nerve stimulation (VNS) within 1 year prior to being screened for the study~* Initiating, changing, or stopping psychotherapy within 6 weeks prior to being screened for the study or at any time during the study~* Investigator or subject anticipates initiating, changing, or stopping non-pharmacologic or alternative therapies for painful physical symptoms at any time during the study~* Are taking any excluded medications within 7 days prior to randomization with the exception of fluoxetine which cannot be taken within 30 days prior to randomization~* Treatment with a monoamine oxidase inhibitor (MAOI) within 14 days prior to randomization or have the potential need to use an MAOI during the study or within 5 days of discontinuing study drug~* Frequent and/or severe allergic reactions with multiple medications~* Abnormal thyroid stimulating hormone concentration~* Has epilepsy or history of seizure disorder or received treatment with anticonvulsant medication for epilepsy or seizures

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Duloxetine (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).